Pharma major Biocon Tuesday said the company retains economic interest in global commercialisation of Hulio in-licensed by Mylan.
"Following the successful approval and European launch of Hulio, (biosimilar Adalimumab) in-licensed by our partner Mylan from Fujifilm Kyowa Kirin Biologics, the commercialisation rights have been extended from Europe to global markets," it said in a regulatory filing.
Biocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing arrangement and will gain a share of profits from global markets, it said.
"Biocon is committed to enable patient access to affordable biosimilars and this partnership accelerates that process," Biocon spokesperson said in the filing.
Disclaimer: No Business Standard Journalist was involved in creation of this content
